The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EWTX | -29.11% | N/A | N/A | -24% |
| S&P | +11% | +85.61% | +13.15% | +66% |
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.57M | -1.2% |
| Market Cap | $1.71B | -31.7% |
| Market Cap / Employee | $12.56M | 0.0% |
| Employees | 136 | 25.9% |
| Net Income | -$40.67M | -19.2% |
| EBITDA | -$46.29M | -16.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $46.00M | 2.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.17M | -8.0% |
| Short Term Debt | $1.01M | 1.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -28.73% | 1.5% |
| Return On Invested Capital | -21.66% | 2.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$34.87M | -25.0% |
| Operating Free Cash Flow | -$34.78M | -27.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.16 | 4.54 | 2.90 | 2.90 | -40.76% |
| Price to Tangible Book Value | 5.16 | 4.54 | 2.90 | 2.90 | -40.76% |
| Enterprise Value to EBITDA | -45.95 | -36.58 | -18.70 | -24.89 | -50.78% |
| Return on Equity | -34.4% | -30.3% | -27.4% | -30.0% | -5.89% |
| Total Debt | $4.74M | $4.56M | $4.37M | $4.18M | -5.83% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
